GlobeNewswire 2022-02-22 Oxurion NV announces 2021 Full Year Results and 2022 Outlook
GlobeNewswire 2022-02-14 Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis...
GlobeNewswire 2022-02-11 Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiog...
GlobeNewswire 2022-02-08 Oxurion to Participate in the 2022 BIO CEO and Investor Conference
GlobeNewswire 2022-01-18 OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference
GlobeNewswire 2022-01-07 Oxurion Provides Update on Clinical Pipeline Progress
GlobeNewswire 2022-01-04 OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
GlobeNewswire 2021-11-30 Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEG...
GlobeNewswire 2021-11-24 OXURION to Present at the Ophthalmology Day at BTIG
GlobeNewswire 2021-11-22 OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventur...
GlobeNewswire 2021-11-15 OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrat...
GlobeNewswire 2021-11-04 Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommen...
GlobeNewswire 2021-10-14 AGTC Announces Two Key Leadership Team Appointments
GlobeNewswire 2021-10-13 Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment o...
GlobeNewswire 2021-10-11 OXURION - Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Specialists ...
GlobeNewswire 2021-10-05 Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
GlobeNewswire 2021-10-05 OXURION to Present at the Lytham Partners Fall 2021 Investor Conference
GlobeNewswire 2021-09-30 OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of ...
GlobeNewswire 2021-09-09 Oxurion NV Business & Financial Update – H1 2021
GlobeNewswire 2021-09-09 Usio to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
GlobeNewswire 2021-09-09 Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conf...
GlobeNewswire 2021-09-08 OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress
GlobeNewswire 2021-08-17 Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME i...
GlobeNewswire 2021-08-16 Oxurion NV - Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of...
GlobeNewswire 2021-08-05 OXURION to Participate in Upcoming Investor Meetings